(Q34677568)

3 August 2017

1 reference

title

Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention (English)

1 reference

3 August 2017

0 references

0 references

1 reference

1 reference

5

Hilkka Soininen

0 references

Jaakko Tuomilehto

3

Jaakko Tuomilehto

0 references

Miia Kivipelto

Miia Kivipelto

1

0 references

Mikko P Laakso

Mikko P Laakso

2

0 references

Aulikki Nissinen

4

Aulikki Nissinen

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

16

1 reference

3 August 2017

7

1 reference

3 August 2017

435-444

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200216070-00001

3 August 2017

0 references

cites work

Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study

1 reference

12 December 2020

Midlife blood pressure and dementia: the Honolulu-Asia aging study.

1 reference

12 December 2020

Copernicus revisited: amyloid beta in Alzheimer's disease

1 reference

12 December 2020

15-year longitudinal study of blood pressure and dementia

1 reference

12 December 2020

Statins and the risk of dementia

1 reference

12 December 2020

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

12 December 2020

The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease

1 reference

12 December 2020

Cholesterol, A beta and Alzheimer's disease

1 reference

12 December 2020

Actual blood pressure control: are we doing things right?

1 reference

12 December 2020

Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

1 reference

12 December 2020

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

1 reference

12 December 2020

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

1 reference

12 December 2020

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

1 reference

12 December 2020

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

1 reference

12 December 2020

APOE genotype, plasma lipids, lipoproteins, and AD in community elderly.

1 reference

12 December 2020

Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults

1 reference

12 December 2020

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

1 reference

12 December 2020

Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study

1 reference

12 December 2020

Effects of lovastatin on cognitive function and psychological well-being

1 reference

12 December 2020

Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.

1 reference

12 December 2020

Vascular factors and Alzheimer disease

1 reference

12 December 2020

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

12 December 2020

Are vascular factors involved in Alzheimer's disease? Facts and theories

1 reference

12 December 2020

Are cognitive function and blood pressure related?

1 reference

12 December 2020

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

1 reference

12 December 2020

Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension

1 reference

12 December 2020

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

1 reference

12 December 2020

Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.

1 reference

12 December 2020

Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use.

1 reference

12 December 2020

Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?

1 reference

12 December 2020

Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.

1 reference

12 December 2020

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

12 December 2020

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

12 December 2020

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

1 reference

12 December 2020

Neurologic consequences of hypertension and antihypertensive drug therapy.

1 reference

12 December 2020

Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study

1 reference

12 December 2020

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

1 reference

12 December 2020

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

1 reference

12 December 2020

Antihypertensive drugs and incidence of dementia: the Rotterdam Study

1 reference

12 December 2020

Cholesterol and Alzheimer's disease: is there a link?

1 reference

12 December 2020

The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients

1 reference

12 December 2020

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

1 reference

12 December 2020

Alzheimer's disease and vascular dementia. Some points of confluence

1 reference

12 December 2020

The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease.

1 reference

12 December 2020

Use of statins in CNS disorders

1 reference

12 December 2020

Overlap between pathology of Alzheimer disease and vascular dementia

1 reference

12 December 2020

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

12 December 2020

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

1 reference

12 December 2020

Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997

1 reference

12 December 2020

A fluid connection: cholesterol and Abeta

1 reference

12 December 2020

Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain

1 reference

12 December 2020

Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study.

1 reference

12 December 2020

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

12 December 2020

10.2165/00023210-200216070-00001

Identifiers

DOI

1 reference

PubMed ID

12056919

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

12056919